EPM2A anticorps (Isoform 9)
-
- Antigène Voir toutes EPM2A Anticorps
- EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
-
Épitope
- AA 1-331, Isoform 9
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp EPM2A est non-conjugé
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)
- Réactivité croisée
- Humain, Souris
- Purification
- >95%, Protein G purified
- Immunogène
- Recombinant Human Laforin, isoform 9 protein (1-331AA)
- Isotype
- IgG
- Top Product
- Discover our top product EPM2A Anticorps primaire
-
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 101-199) antibody
EPM2A Reactivité: Humain WB, ELISA Hôte: Souris Monoclonal 6C6 unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (C-Term) antibodyEPM2A Reactivité: Humain WB, IF, IHC (p), ICC Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 244-331) antibodyEPM2A Reactivité: Humain ELISA, IHC Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) antibodyEPM2A Reactivité: Humain, Rat, Souris ELISA, IHC Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 1-331) antibodyEPM2A Reactivité: Humain WB, IP Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 243-331) antibodyEPM2A Reactivité: Humain WB, ELISA, IF, ICC Hôte: Souris Monoclonal k2A3 unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 80-130) antibodyEPM2A Reactivité: Humain, Boeuf (Vache) WB, IHC, IHC (p) Hôte: Lapin Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 101-199) antibodyEPM2A Reactivité: Humain WB, ELISA Hôte: Souris Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 1-331) antibodyEPM2A Reactivité: Humain WB Hôte: Souris Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 244-331) antibodyEPM2A Reactivité: Humain WB Hôte: Lapin Polyclonal unconjugated
-
- Indications d'application
- Recommended dilution: WB:1:2000-1:5000, IHC:1:20-1:200, IF:1:50-1:200,
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4 - Agent conservateur
- ProClin
- Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- -20 °C,-80 °C
- Stockage commentaire
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Antigène
- EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
- Autre désignation
- EPM2A (EPM2A Produits)
- Synonymes
- anticorps TG-B, anticorps Tg(TcraK,TcrbK)TG-BFlv, anticorps EPM2, anticorps MELF, anticorps laforin, anticorps EPM2A, laforin glucan phosphatase, anticorps epilepsy, progressive myoclonic epilepsy, type 2 gene alpha, anticorps EPM2A, anticorps Epm2a
- Sujet
-
Background: negative regulation of TOR signaling, positive regulation of macroautophagy
Aliases: EPM2ALaforin antibody, isoform 9 antibody
- UniProt
- B3EWF7
- Pathways
- Cellular Glucan Metabolic Process
-
